FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385655176> ?p ?o ?g. }

• W4385655176 endingPage "e029085e" @default.
• W4385655176 startingPage "e029085e" @default.
• W4385655176 abstract "Topic: 16. Myeloproliferative neoplasms - Clinical Background: The goal of therapy of polycythemia vera (PV) and essential thrombocythemia (ET) is primarily to prevent vascular events that are the leading cause of morbidity and mortality. Patients older than 60 years or with a previous history of thrombotic complications are considered at high risk of thrombosis. Aims: The aim of this study was to explore the incidence of thrombotic events and long-term outcomes in high-risk patients with JAK2 V617F positive PV or ET. Methods: We retrospectively evaluated the clinical outcomes of JAK2 V617F positive PV and ET at a high risk of thrombosis. The patients older than 60 years of age and/or had a history of thrombosis at diagnosis among patients with JAK2 V617F positive PV or ET from Daegu Catholic University Hospital between 2010 and 2021 were included in this study. Results: A total of 112 patents, median age 73 years, with JAK2 V617F positive PV (n=50) or ET (n=62) were included. One hundred two patients were over 60 years old and 46 patients had a history of thrombosis or thrombotic event at diagnosis. All patients were treated with cytoreductive drugs. The cumulative incidence of thrombosis at 7 years was 29.9%, corresponding to 32.7% in PV and 29.2% in ET patients. Arterial thrombosis (93.8%) predominated in both diseases. Forty-five patients died during the follow-up period. Median overall survival was 125.1 months (95% CI 85.8-164.4). Median thrombosis-free survival was 86 months (95% CI 68.4-103.6). Older age (≥75 years old) and a higher JAK2 V617F allele burden (≥25%) were associated with poor thrombosis-free survival. Estimated rates of thrombosis-free survival at 7 years were 73.9% in the patients with lower JAK2 V617F allele burden (<25%) and 44.1% in the patients with higher JAK2 V617F allele burden (≥25%) (p=0.015). Eleven patients (9.7%) had secondary myelofibrosis, and one patient developed acute myeloid leukemia. Summary/Conclusion: A higher JAK2 V617F allele burden is associated with a higher risk of thrombotic events in patients with high-risk PV and ET. Current therapy remains suboptimal, with ongoing risk for thrombosis and death in high-risk PV and ET patients with higher JAK2 V617F allele burden. A novel approach will be needed in this group. Keywords: Essential Thrombocytemia, Polycythemia vera, Thromboembolic events" @default.
• W4385655176 created "2023-08-09" @default.
• W4385655176 creator A5009504694 @default.
• W4385655176 creator A5054752452 @default.
• W4385655176 creator A5058092939 @default.
• W4385655176 creator A5087021923 @default.
• W4385655176 date "2023-08-01" @default.
• W4385655176 modified "2023-09-27" @default.
• W4385655176 title "PB2192: JAK2 V617F ALLELE BURDEN AND THROMBOTIC EVENTS IN PATIENTS WITH JAK2 V617F POSITIVE POLYCYTHEMIA VERA OR ESSENTIAL THROMBOCYTHEMIA AT HIGH RISK OF THROMBOSIS" @default.
• W4385655176 doi "https://doi.org/10.1097/01.hs9.0000975520.02908.5e" @default.
• W4385655176 hasPublicationYear "2023" @default.
• W4385655176 type Work @default.
• W4385655176 citedByCount "0" @default.
• W4385655176 crossrefType "journal-article" @default.
• W4385655176 hasAuthorship W4385655176A5009504694 @default.
• W4385655176 hasAuthorship W4385655176A5054752452 @default.
• W4385655176 hasAuthorship W4385655176A5058092939 @default.
• W4385655176 hasAuthorship W4385655176A5087021923 @default.
• W4385655176 hasBestOaLocation W43856551761 @default.
• W4385655176 hasConcept C120665830 @default.
• W4385655176 hasConcept C121332964 @default.
• W4385655176 hasConcept C126322002 @default.
• W4385655176 hasConcept C141071460 @default.
• W4385655176 hasConcept C187212893 @default.
• W4385655176 hasConcept C2778837598 @default.
• W4385655176 hasConcept C2780868729 @default.
• W4385655176 hasConcept C2781057849 @default.
• W4385655176 hasConcept C2781179581 @default.
• W4385655176 hasConcept C61511704 @default.
• W4385655176 hasConcept C71924100 @default.
• W4385655176 hasConcept C72563966 @default.
• W4385655176 hasConcept C88879693 @default.
• W4385655176 hasConcept C90924648 @default.
• W4385655176 hasConceptScore W4385655176C120665830 @default.
• W4385655176 hasConceptScore W4385655176C121332964 @default.
• W4385655176 hasConceptScore W4385655176C126322002 @default.
• W4385655176 hasConceptScore W4385655176C141071460 @default.
• W4385655176 hasConceptScore W4385655176C187212893 @default.
• W4385655176 hasConceptScore W4385655176C2778837598 @default.
• W4385655176 hasConceptScore W4385655176C2780868729 @default.
• W4385655176 hasConceptScore W4385655176C2781057849 @default.
• W4385655176 hasConceptScore W4385655176C2781179581 @default.
• W4385655176 hasConceptScore W4385655176C61511704 @default.
• W4385655176 hasConceptScore W4385655176C71924100 @default.
• W4385655176 hasConceptScore W4385655176C72563966 @default.
• W4385655176 hasConceptScore W4385655176C88879693 @default.
• W4385655176 hasConceptScore W4385655176C90924648 @default.
• W4385655176 hasIssue "S3" @default.
• W4385655176 hasLocation W43856551761 @default.
• W4385655176 hasLocation W43856551762 @default.
• W4385655176 hasOpenAccess W4385655176 @default.
• W4385655176 hasPrimaryLocation W43856551761 @default.
• W4385655176 hasRelatedWork W1986560933 @default.
• W4385655176 hasRelatedWork W2012509591 @default.
• W4385655176 hasRelatedWork W2131294717 @default.
• W4385655176 hasRelatedWork W2139860886 @default.
• W4385655176 hasRelatedWork W2577164226 @default.
• W4385655176 hasRelatedWork W3015241011 @default.
• W4385655176 hasRelatedWork W3187057186 @default.
• W4385655176 hasRelatedWork W3205070829 @default.
• W4385655176 hasRelatedWork W4245105484 @default.
• W4385655176 hasRelatedWork W4385655176 @default.
• W4385655176 hasVolume "7" @default.
• W4385655176 isParatext "false" @default.
• W4385655176 isRetracted "false" @default.
• W4385655176 workType "article" @default.